• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characteristics and outcomes of patients presenting with acute myocardial infarction and cardiogenic shock during COVID-19.在 COVID-19 期间出现急性心肌梗死和心源性休克的患者的特征和结局。
Catheter Cardiovasc Interv. 2022 Oct;100(4):568-574. doi: 10.1002/ccd.30390. Epub 2022 Sep 7.
2
Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock Initiative.休克方案的应用与改善预后相关:国家心源性休克倡议的最新进展。
Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1173-1183. doi: 10.1002/ccd.28307. Epub 2019 Apr 25.
3
Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: The Detroit cardiogenic shock initiative.急性心肌梗死合并心源性休克早期机械循环支持的可行性:底特律心源性休克倡议
Catheter Cardiovasc Interv. 2018 Feb 15;91(3):454-461. doi: 10.1002/ccd.27427. Epub 2017 Dec 20.
4
Vasopressors independently associated with mortality in acute myocardial infarction and cardiogenic shock.血管加压素与急性心肌梗死和心源性休克患者的死亡率独立相关。
Catheter Cardiovasc Interv. 2022 Feb;99(3):650-657. doi: 10.1002/ccd.29895. Epub 2021 Aug 3.
5
Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock.多血管病变与罪犯血管经皮冠状动脉介入治疗心原性休克。
JACC Cardiovasc Interv. 2020 May 25;13(10):1171-1178. doi: 10.1016/j.jcin.2020.03.012. Epub 2020 Apr 29.
6
Outcomes of mechanical circulatory support for acute myocardial infarction complicated by cardiogenic shock.机械循环支持治疗急性心肌梗死合并心原性休克的疗效。
Catheter Cardiovasc Interv. 2022 Feb;99(3):658-663. doi: 10.1002/ccd.29834. Epub 2021 Jun 22.
7
Impella 2.5 initiated prior to unprotected left main PCI in acute myocardial infarction complicated by cardiogenic shock improves early survival.在急性心肌梗死合并心源性休克患者进行无保护左主干经皮冠状动脉介入治疗(PCI)之前启动Impella 2.5可提高早期生存率。
J Interv Cardiol. 2017 Jun;30(3):256-263. doi: 10.1111/joic.12377. Epub 2017 Apr 17.
8
Outcomes Among Patients Transferred for Revascularization With Impella for Acute Myocardial Infarction With Cardiogenic Shock from the cVAD Registry.从 cVAD 注册研究看因心原性休克行急性心肌梗死伴发的经皮 Impella 辅助血运重建术患者的转归。
Am J Cardiol. 2019 Apr 15;123(8):1214-1219. doi: 10.1016/j.amjcard.2019.01.029. Epub 2019 Jan 25.
9
Treatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study.COVID-19大流行期间急性心肌梗死的治疗延误及院内结局:一项全国性研究。
Anatol J Cardiol. 2020 Nov;24(5):334-342. doi: 10.14744/AnatolJCardiol.2020.98607.
10
Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock.血管内微型轴流左心室辅助装置与主动脉内球囊泵在急性心肌梗死合并心源性休克患者中的应用与院内死亡率和大出血的关系。
JAMA. 2020 Feb 25;323(8):734-745. doi: 10.1001/jama.2020.0254.

引用本文的文献

1
Trends and Outcomes of Acute Myocardial Infarction During the Early COVID-19 Pandemic in the United States: A National Inpatient Sample Study.美国新冠疫情早期急性心肌梗死的趋势与结局:一项全国住院患者样本研究
Korean Circ J. 2024 Nov;54(11):710-723. doi: 10.4070/kcj.2024.0028. Epub 2024 Jun 27.

本文引用的文献

1
Delayed Care with Harmful Health Consequences-Reported Experiences from National Surveys During Coronavirus Disease 2019.延迟就医并带来有害健康后果——2019年冠状病毒病期间全国调查的报告经历
JAMA Health Forum. 2020 Dec 1;1(12):e201463. doi: 10.1001/jamahealthforum.2020.1463.
2
Acute Ischemic Stroke in Patients With COVID-19: An Analysis From Get With The Guidelines-Stroke.COVID-19 患者的急性缺血性脑卒中:来自 Get With The Guidelines-Stroke 的分析。
Stroke. 2021 May;52(5):1826-1829. doi: 10.1161/STROKEAHA.121.034301. Epub 2021 Mar 17.
3
Management of Cardiogenic Shock During COVID-19: The IHVI Experience.2019冠状病毒病期间心源性休克的管理:IHVI经验
J Am Coll Cardiol. 2021 Jan 19;77(2):227-228. doi: 10.1016/j.jacc.2020.11.026.
4
Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction Before and During COVID in New York.纽约在新冠疫情前后对 ST 段抬高型心肌梗死患者进行经皮冠状动脉介入治疗。
Am J Cardiol. 2021 Mar 1;142:25-34. doi: 10.1016/j.amjcard.2020.11.033. Epub 2020 Dec 8.
5
Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID-19 pandemic.新冠肺炎大流行早期急性心肌梗死患者的死亡率增加和心脏预后更差。
ESC Heart Fail. 2021 Feb;8(1):333-343. doi: 10.1002/ehf2.13075. Epub 2020 Dec 6.
6
In-Hospital Management and Outcomes of Acute Myocardial Infarction Before and During the Coronavirus Disease 2019 Pandemic.新冠肺炎疫情前后急性心肌梗死患者的院内管理和结局。
J Cardiovasc Pharmacol. 2020 Nov;76(5):540-548. doi: 10.1097/FJC.0000000000000909.
7
Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic.新型冠状病毒肺炎(COVID-19)大流行期间急性心肌梗死相关的心源性休克发病率
Int J Cardiol Heart Vasc. 2020 Dec;31:100659. doi: 10.1016/j.ijcha.2020.100659. Epub 2020 Oct 13.
8
Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study.根据法国 COVID-19 区域性流行情况和患者特征,封锁前后因急性心肌梗死住院的情况:一项注册研究。
Lancet Public Health. 2020 Oct;5(10):e536-e542. doi: 10.1016/S2468-2667(20)30188-2. Epub 2020 Sep 18.
9
Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns - United States, June 2020.由于对 COVID-19 的担忧而延迟或避免就医-美国,2020 年 6 月。
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257. doi: 10.15585/mmwr.mm6936a4.
10
Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction.COVID-19 对 ST 段抬高型心肌梗死经皮冠状动脉介入治疗的影响。
Heart. 2020 Dec;106(23):1805-1811. doi: 10.1136/heartjnl-2020-317650. Epub 2020 Aug 31.

在 COVID-19 期间出现急性心肌梗死和心源性休克的患者的特征和结局。

Characteristics and outcomes of patients presenting with acute myocardial infarction and cardiogenic shock during COVID-19.

机构信息

Department of Medicine, Ronald Reagan-UCLA Medical Center, Los Angeles, California, USA.

Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, California, USA.

出版信息

Catheter Cardiovasc Interv. 2022 Oct;100(4):568-574. doi: 10.1002/ccd.30390. Epub 2022 Sep 7.

DOI:10.1002/ccd.30390
PMID:36073018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9539126/
Abstract

OBJECTIVES

To evaluate characteristics and outcomes of patients presenting with acute myocardial infarction and cardiogenic shock (AMICS) during the coronavirus disease 2019 (COVID-19) pandemic.

BACKGROUND

The COVID-19 pandemic has created challenges in delivering acute cardiovascular care. Quality measures and outcomes of patients presenting with AMICS during COVID-19 in the United States have not been well described.

METHODS

We identified 406 patients from the National Cardiogenic Shock Initiative (NCSI) with AMICS and divided them into those presenting before (N = 346, 5/9/2016-2/29/2020) and those presenting during the COVID-19 pandemic (N = 60, 3/1/2020-11/10/2020). We compared baseline clinical data, admission characteristics, and outcomes.

RESULTS

The median age of the cohort was 64 years, and 23.7% of the group was female. There were no significant differences in age, sex, and medical comorbidities between the two groups. Patients presenting during the pandemic were less likely to be Black compared to those presenting prior. Median door to balloon (90 vs. 88 min, p = 0.38), door to support (88 vs. 78 min, p = 0.13), and the onset of shock to support (74 vs. 62 min, p = 0.15) times were not significantly different between the two groups. Patients presented with ST-elevation myocardial infarction more often during the COVID-19 period (95.0% vs. 80.0%, p = 0.005). In adjusted logistic regression models, COVID-19 period did not significantly associate with survival to discharge (odds ratio [OR] 1.09, 95% confidence interval [CI] 0.54-2.19, p = 0.81) or with 1-month survival (OR 0.82, 95% CI 0.42-1.61, p = 0.56).

CONCLUSIONS

Care of patients presenting with AMICS has remained robust among hospitals participating in the NCSI during the COVID-19 pandemic.

摘要

目的

评估在 2019 年冠状病毒病(COVID-19)大流行期间出现急性心肌梗死合并心原性休克(AMICS)的患者的特征和结局。

背景

COVID-19 大流行给急性心血管治疗带来了挑战。美国在 COVID-19 期间出现 AMICS 的患者的质量指标和结局尚未得到很好的描述。

方法

我们从国家心原性休克倡议(NCSI)中确定了 406 名 AMICS 患者,并将其分为在 COVID-19 大流行之前(N = 346,2016 年 5 月 9 日至 2020 年 2 月 29 日)和 COVID-19 大流行期间(N = 60,2020 年 3 月 1 日至 11 月 10 日)就诊的患者。我们比较了两组的基线临床数据、入院特征和结局。

结果

该队列的中位年龄为 64 岁,其中 23.7%为女性。两组间在年龄、性别和合并症方面无显著差异。与之前就诊的患者相比,大流行期间就诊的患者黑人比例较低。两组间门球时间(90 分钟 vs. 88 分钟,p = 0.38)、门支持时间(88 分钟 vs. 78 分钟,p = 0.13)和休克发生至支持时间(74 分钟 vs. 62 分钟,p = 0.15)均无显著差异。在 COVID-19 期间,患者更常出现 ST 段抬高型心肌梗死(95.0% vs. 80.0%,p = 0.005)。在调整后的逻辑回归模型中,COVID-19 期与出院时存活(比值比[OR] 1.09,95%置信区间[CI] 0.54-2.19,p = 0.81)或 1 个月存活(OR 0.82,95%CI 0.42-1.61,p = 0.56)无显著相关性。

结论

在 COVID-19 大流行期间,参与 NCSI 的医院对出现 AMICS 的患者的治疗仍然稳健。